Phase 3 trial data show subcutaneous anifrolumab improves BICLA response rates and reduces oral corticosteroid use in ...

Three years after the accelerated approval of its anti-amyloid Alzheimer’s therapy, Biogen—neck and neck in the market with ...

Subcutaneous anifrolumab (Saphnelo) added to standard therapy significantly improves treatment outcomes in patients with ...

A subcutaneous version of the newly approved Alzheimer's drug lecanemab (Leqembi) may be on the horizon. Weekly subcutaneous lecanemab 100 mg/mL injection appeared to be as effective at amyloid plaque ...

Argenx has filed for FDA approval of subcutaneous efgartigimod, keeping it on track to start selling the sibling of its existing intravenous generalized myasthenia gravis (gMG) treatment Vyvgart. In ...

As with the intravenous form, subcutaneous anifrolumab shows clinically meaningful benefits and favorable safety when added ...

Considering a switch from IVIg to SCIg for primary immunodeficiency? Explore differences in responsibility, side effects, costs, and how each impacts quality of life.

Market Dynamix™ is an independent, data-driven service focused on understanding the evolving dynamics of specialty markets poised for disruption. Leveraging quantitative and qualitative research, the ...

Argenx’s subcutaneous formulation of the active ingredient in Vyvgart has hit the primary endpoint in a phase 3 trial, clearing the biotech to file for approval of a product it expects to become the ...

If approved, lecanemab may become the first and only anti-amyloid treatment in China to offer an at-home injection from the ...

Subcutaneous fat is stored just beneath the skin and can be pinched with your fingers. Visceral fat lies deep within the abdominal walls and surrounds the organs. Visceral fat tends to cause bad ...

Please provide your email address to receive an email when new articles are posted on . Laurenzano, Marinkovic and colleagues conducted a retrospective study analyzing subcutaneous testosterone as ...